腫瘍治療薬の中国市場:化学療法、標的療法、免疫療法、ホルモン療法

◆英語タイトル:China Oncology Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, Kidney Cancer, and Other Cancers): Opportunity Analysis and Industry Forecast, 2019-2026
◆商品コード:AMR9NV120
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2019年8月
◆ページ数:135
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:中国
◆販売価格オプション(消費税別)
Single UserUSD5,370 ⇒換算¥558,480見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算¥670,800見積依頼/購入/質問フォーム
Enterprise UserUSD8,995 ⇒換算¥935,480見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

The China oncology drugs market was valued at $6,498.2 million in 2018 and is projected to reach $12,688.7 million by 2026, registering a CAGR of 8.7% from 2019 to 2026. Cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer according to the data published by WHO. Being the most populous country in the world, cancer rates are significantly rising in China. As per Global Cancer Observatory in 2018, the number of new cancer cases registered each year in China are 4,285,033. Amongst which, lung cancer constitutes 18.1%; colorectum cancer is about 12.2%; stomach cancer is approximately 10.6%; liver cancer constitutes 9.2%; breast cancer comprises of 8.6% and 41.1% other cancers. The population of China accounts for 19.3% of the global population, and the incidence rate of cancer accounts for 22% of global cancer incidence, ranking first in the world. Cancer deaths in China account for about 27% of global cancer deaths. Cancer mortality in China is also higher than the global average of 17%.
Rise in incidence of various cancer conditions, aging population, westernized diet, shift to sedentary lifestyle, and surge in tobacco smoke exposure due to urbanization in China are the key factors that drive the growth of the cancer. This in turn boosts the growth of the China oncology drugs market. Furthermore, rise in cancer awareness and increase in availability of cancer drugs are expected to boost the market growth. However, the use of traditional Chinese medicine (TCM) to cure cancer and high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies are expected to restrain the growth of the market. Conversely, high potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future.

The China oncology drugs market is segmented based on drug class type and indication. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. By indication, it is categorized into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer, ovarian cancer, cervical cancer, kidney cancer, and other cancers.

KEY MARKET BENEFITS
• This report entails a detailed quantitative analysis along with the current China oncology drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The market forecast is studied from 2019 to 2026.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

Key market segments
By Drug Class Type
• Chemotherapy
• Targeted Therapy
• Immunotherapy Therapy
• Hormonal Therapy
By Indication
• Blood Cancer
• Breast Cancer
• Gastrointestinal Cancer
• Prostate Cancer
• Lung Cancer
• Skin Cancer
• Ovarian Cancer
• Cervical Cancer
• Kidney Cancer
• Other Cancers

LIST of KEY PLAYERS PRofILED IN THE REPORT
• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Celgene Corporation
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Shanghai Junshi Biosciences Co., Ltd.
• Beigene
• Jiangsu Hengrui Medicine Co., Ltd

【レポートの目次】

Chapter 1: Introduction

1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments

1.3.1. List of Key Players Profiled In The Report

1.4. Research Methodology

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1. Key Findings of The Study
2.2. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope
3.2. Key Findings

3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies, 2018

3.3. Porter’S Five Forces Analysis
3.4. Market Dynamics

3.4.1. Drivers

3.4.1.1. Industrial Collaboration
3.4.1.2. In House Manufacturing
3.4.1.3. Increase In Incidences of Cancers In The Chinese Population

3.4.2. Restraint

3.4.2.1. Preference of Generics And Biosimilars

3.4.3. Opportunity

3.4.3.1. Increase In Number of Pipeline Drugs

3.4.4. Impact Analyses

Chapter 4: China Oncology Drugs Market, By Drug Class Type

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Chemotherapy

4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast

4.3. Targeted Therapy

4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast

4.4. Immunotherapy (Biologic Therapy)

4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast

4.5. Hormonal Therapy

4.5.1. Key Market Trends, Growth Factors, And Opportunities
4.5.2. Market Size And Forecast

Chapter 5: China Oncology Drugs Market, By Indication

5.1. Overview

5.1.1. Cancer Incidences In China, 2018
5.1.2. Market Size And Forecast

5.2. Blood Cancer

5.2.1. Market Size And Forecast

5.3. Breast Cancer

5.3.1. Market Size And Forecast

5.4. Gastrointestinal And Urinary Cancer

5.4.1. Market Size And Forecast
5.4.2. Gb/Cholangiocarcinoma

5.4.2.1. Market Size And Forecast

5.4.3. Bladder Cancer

5.4.3.1. Market Size And Forecast

5.4.4. Pancreatic Cancer

5.4.4.1. Market Size And Forecast

5.5. Prostate Cancer

5.5.1. Market Size And Forecast

5.6. Lung Cancer

5.6.1. Market Size And Forecast
5.6.2. Small Cell Lung Cancer (Sclc)

5.6.2.1. Market Size And Forecast

5.7. Skin Cancer

5.7.1. Market Size And Forecast

5.8. Ovarian Cancer

5.8.1. Market Size And Forecast

5.9. Cervical Cancer

5.9.1. Market Size And Forecast

5.10. Kidney Cancer

5.10.1. Market Size And Forecast,

5.11. Other Cancers

5.11.1. Market Size And Forecast

Chapter 6: Company Profiles

6.1. Abbvie Inc.

6.1.1. Company Overview
6.1.2. Company Snapshot
6.1.3. Operating Business Segments
6.1.4. Product Portfolio
6.1.5. Business Performance

6.2. Astellas Pharma Inc.

6.2.1. Company Overview
6.2.2. Company Snapshot
6.2.3. Operating Business Segments
6.2.4. Product Portfolio
6.2.5. Business Performance

6.3. Astrazeneca Plc

6.3.1. Company Overview
6.3.2. Company Snapshot
6.3.3. Operating Business Segments
6.3.4. Product Portfolio
6.3.5. Business Performance

6.4. Bristol-Myers Squibb Company

6.4.1. Company Overview
6.4.2. Company Snapshot
6.4.3. Operating Business Segments
6.4.4. Product Portfolio
6.4.5. Business Performance
6.4.6. Key Strategic Moves And Developments

6.5. Celgene Corporation

6.5.1. Company Overview
6.5.2. Company Snapshot
6.5.3. Operating Business Segments
6.5.4. Product Portfolio
6.5.5. Business Performance
6.5.6. Key Strategic Moves And Developments

6.6. F. Hoffmann-La Roche Ltd.

6.6.1. Company Overview
6.6.2. Company Snapshot
6.6.3. Operating Business Segments
6.6.4. Product Portfolio
6.6.5. Business Performance
6.6.6. Key Strategic Moves And Developments

6.7. Johnson & Johnson

6.7.1. Company Overview
6.7.2. Company Snapshot
6.7.3. Operating Business Segments
6.7.4. Product Portfolio
6.7.5. Business Performance
6.7.6. Key Strategic Moves And Developments

6.8. Shanghai Junshi Biosciences Co., Ltd.

6.8.1. Company Overview
6.8.2. Company Snapshot
6.8.3. Operating Business Segments
6.8.4. Product Portfolio
6.8.5. Business Performance
6.8.6. Key Strategic Moves And Developments

6.9. Beigene

6.9.1. Company Overview
6.9.2. Company Snapshot
6.9.3. Operating Business Segments
6.9.4. Product Portfolio
6.9.5. Business Performance
6.9.6. Key Strategic Moves And Developments

6.10. Jiangsu Hengrui Medicine Co., Ltd.

6.10.1. Company Overview
6.10.2. Company Snapshot
6.10.3. Operating Business Segments
6.10.4. Product Portfolio
6.10.5. Key Strategic Moves And Developments

List of Tables

Table 01. China Oncology Drugs Market, By Drug Class Type, 2018-2026 ($Million)
Table 02. China Oncology Drugs Market, List of Chemotherapy Drugs
Table 03. China Oncology Drugs Market, List of Targeted Therapy Drugs
Table 04. China Oncology Drugs Market, List of Immunotherapeutic Drugs
Table 05. China Oncology Drugs Market, List of Hormonal Therapy Drugs
Table 06. China Oncology Drugs Market, By Indication, 2018–2026 ($Million)
Table 07. Abbvie: Company Snapshot
Table 08. Abbvie: Operating Segments
Table 09. Abbvie: Product Portfolio
Table 10. Astellas: Company Snapshot
Table 11. Astellas: Products And Services
Table 12. Astellas: Product Portfolio
Table 13. Astrazeneca: Company Snapshot
Table 14. Astrazeneca: Operating Segments
Table 15. Astrazeneca: Product Portfolio
Table 16. Bristol-Myers Squibb: Company Snapshot
Table 17. Bristol-Myers Squibb: Product Portfolio
Table 18. Celgene: Company Snapshot
Table 19. Celgene: Operating Segments
Table 20. Celgene: Product Type Portfolio
Table 21. Roche: Company Snapshot
Table 22. Roche: Operating Segments
Table 23. Roche: Product Type Portfolio
Table 24. J&J: Company Snapshot
Table 25. J&J: Operating Segments
Table 26. J&J: Product Type Portfolio
Table 27. Shanghai Junshi Biosciences Co., Ltd.: Company Snapshot
Table 28. Shanghai Junshi Biosciences Co., Ltd: Operating Segments
Table 29. Shanghai Junshi Biosciences Co., Ltd.: Product Type Portfolio
Table 30. Beigene: Company Snapshot
Table 31. Beigene: Operating Segments
Table 32. Beigene: Product Type Portfolio
Table 33. Jiangsu Hengrui Medicine Co., Ltd: Company Snapshot
Table 34. Jiangsu Hengrui Medicine Co., Ltd: Operating Segments
Table 35. Jiangsu Hengrui Medicine Co., Ltd: Product Type Portfolio

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[腫瘍治療薬の中国市場:化学療法、標的療法、免疫療法、ホルモン療法]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆